ANI Pharmaceuticals (NASDAQ:ANIP) Stock Rating Reaffirmed by Guggenheim

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at Guggenheim in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $77.00 target price on the specialty pharmaceutical company's stock. Guggenheim's price objective suggests a potential upside of 16.42% from the stock's current price.

Several other brokerages have also commented on ANIP. Truist Financial increased their price target on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a "buy" rating in a research note on Friday, March 1st. Capital One Financial initiated coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 15th. They issued an "overweight" rating and a $80.00 target price on the stock. Finally, HC Wainwright raised their target price on shares of ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a "buy" rating in a research note on Monday, March 4th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $80.00.

ANI Pharmaceuticals Price Performance

ANIP stock traded up $0.52 on Tuesday, hitting $66.14. 85,940 shares of the company's stock traded hands, compared to its average volume of 138,397. ANI Pharmaceuticals has a 1-year low of $36.99 and a 1-year high of $70.81. The stock has a market cap of $1.39 billion, a price-to-earnings ratio of 78.74 and a beta of 0.79. The stock has a fifty day moving average of $65.12 and a 200-day moving average of $58.70. The company has a current ratio of 3.57, a quick ratio of 2.81 and a debt-to-equity ratio of 0.66.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $131.65 million during the quarter, compared to the consensus estimate of $123.02 million. ANI Pharmaceuticals had a net margin of 3.86% and a return on equity of 18.06%. On average, analysts forecast that ANI Pharmaceuticals will post 3.55 EPS for the current fiscal year.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, SVP Chad Gassert sold 20,000 shares of the firm's stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $67.25, for a total transaction of $1,345,000.00. Following the completion of the transaction, the senior vice president now directly owns 253,226 shares of the company's stock, valued at approximately $17,029,448.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, SVP Chad Gassert sold 20,000 shares of ANI Pharmaceuticals stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $67.25, for a total transaction of $1,345,000.00. Following the completion of the transaction, the senior vice president now directly owns 253,226 shares of the company's stock, valued at approximately $17,029,448.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP James G. Marken sold 24,338 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $66.37, for a total transaction of $1,615,313.06. Following the transaction, the senior vice president now directly owns 124,492 shares of the company's stock, valued at $8,262,534.04. The disclosure for this sale can be found here. Insiders sold a total of 156,803 shares of company stock valued at $10,363,466 in the last ninety days. Company insiders own 12.70% of the company's stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Global Alpha Capital Management Ltd. increased its position in ANI Pharmaceuticals by 15.9% in the 3rd quarter. Global Alpha Capital Management Ltd. now owns 525,528 shares of the specialty pharmaceutical company's stock valued at $30,512,000 after acquiring an additional 72,200 shares in the last quarter. ClariVest Asset Management LLC grew its position in shares of ANI Pharmaceuticals by 36.7% during the 3rd quarter. ClariVest Asset Management LLC now owns 51,338 shares of the specialty pharmaceutical company's stock worth $2,980,000 after buying an additional 13,792 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of ANI Pharmaceuticals by 287.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 146,989 shares of the specialty pharmaceutical company's stock worth $8,534,000 after buying an additional 109,015 shares during the period. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of ANI Pharmaceuticals during the 3rd quarter worth approximately $685,000. Finally, EAM Investors LLC acquired a new stake in shares of ANI Pharmaceuticals during the 3rd quarter worth approximately $1,489,000. Institutional investors and hedge funds own 76.05% of the company's stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.